Treatment of Hematemesis in Hepatocellular Carcinoma
For a patient with HCC presenting with hematemesis (blood vomiting), immediate management depends on whether this represents variceal bleeding from underlying cirrhosis versus tumor rupture with hemoperitoneum—if the patient has preserved liver function (Child-Pugh A or B7) and a resectable tumor with confirmed hemoperitoneum, emergency surgical resection is the treatment of choice; otherwise, transcutaneous arterial embolization (TAE) should be performed urgently. 1
Critical Initial Assessment
The first priority is determining the source of bleeding:
- Variceal bleeding from portal hypertension (most common in cirrhotic HCC patients) versus spontaneous tumor rupture with hemoperitoneum (occurs in 4.8-26% of HCC cases) 1
- Perform urgent ultrasonography and/or CT scan to identify hemoperitoneum and assess tumor characteristics 1
- Assess liver functional reserve using Child-Pugh classification immediately 1
Management Algorithm for Spontaneous HCC Rupture
Emergency Surgical Resection (Preferred if criteria met)
Indications for emergency surgery: 1
- Child-Pugh class A or B7 (preserved liver function)
- Single resectable hepatic tumor identified on imaging
- Confirmed hemoperitoneum on ultrasound/CT
- Patient can tolerate general anesthesia
Surgical outcomes: 1
- Emergency liver resection achieves superior early and long-term results compared to TAE
- Mortality risk is acceptable when patient selection is appropriate
- Typical procedures include minor resections (lobectomy, segmentectomy, or wedge resection)
Transcutaneous Arterial Embolization (TAE)
Indications for TAE: 1
- Poor liver function (Child-Pugh B8 or worse)
- Unresectable tumor (multiple nodules, unfavorable location, or large tumor burden)
- Patient unable to tolerate emergency surgery
- As a bridge procedure after surgical packing for unstable patients
Important caveat: All patients treated with TAE alone in the available evidence died within 6 months, indicating this is a temporizing measure rather than definitive treatment 1
Salvage Options
Surgical hemostasis or hepatic artery ligation should be reserved exclusively for: 1
- Uncontrollable bleeding after failed TAE
- Recurrent bleeding after initial TAE
Management of Variceal Bleeding
If the hematemesis is from esophageal or gastric varices (not tumor rupture):
- Standard variceal bleeding protocols apply (endoscopic band ligation, octreotide, antibiotics)
- Critical consideration: Patients being considered for atezolizumab plus bevacizumab therapy must have variceal bleeding risk assessed and managed before initiating bevacizumab due to bleeding risk 2
- Variceal screening and prophylaxis are mandatory before starting anti-angiogenic systemic therapies 2
Post-Acute Management
After stabilization of acute bleeding:
- For surgical candidates post-resection: Monitor for recurrence with surveillance imaging; consider adjuvant atezolizumab plus bevacizumab (though longer-term data needed) 2
- For TAE-treated patients: Transition to definitive HCC treatment based on tumor stage and liver function once stabilized 2
- Intermediate-stage disease: TACE, conventional TAE, or drug-eluting bead TACE are standard options for patients with preserved liver function (Child A or B7 without ascites) 2
Common Pitfalls
- Do not delay imaging: Rapid ultrasound/CT is essential to differentiate tumor rupture from variceal bleeding 1
- Do not attempt emergency resection in decompensated cirrhosis: This carries prohibitive mortality; TAE is the only option 1
- Do not use TACE/TAE in patients with: decompensated liver disease, advanced kidney dysfunction, macroscopic vascular invasion, or extrahepatic spread 2
- Avoid surgical packing as definitive treatment: This should only be used as a bridge to either resection or TAE 1